Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus chemotherapy vs placebo in recurrent/metastatic head and neck squamous cell carcinoma
CTR20190292Phase 3Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in head and neck squamous cell carcinoma (HNSCC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Feb 2019; status: terminated.
02
Drugs
benmelstobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20190292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190292.